
USD
+$0.00
(+0.00%
)At Close (As of Nov 14, 2025)
$24.58B
Market Cap
15.27
P/E Ratio
10.97
EPS
$169.00
52 Week High
$110.04
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $7.4B |
| Total Revenue | $9.7B |
| Cost Of Revenue | $2.3B |
| Costof Goods And Services Sold | $2.3B |
| Operating Income | $2.5B |
| Selling General And Administrative | $2.3B |
| Research And Development | $2.5B |
| Operating Expenses | $4.9B |
| Investment Income Net | - |
| Net Interest Income | -$183M |
| Interest Income | $68M |
| Interest Expense | $250M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $673M |
| Income Before Tax | $1.9B |
| Income Tax Expense | $274M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.6B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.3B |
| Ebitda | $3B |
| Net Income | $1.6B |
| Field | Value (USD) |
|---|---|
| Total Assets | $28B |
| Total Current Assets | $7.5B |
| Cash And Cash Equivalents At Carrying Value | $2.4B |
| Cash And Short Term Investments | $2.4B |
| Inventory | $2.5B |
| Current Net Receivables | $1.9B |
| Total Non Current Assets | $21B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $9.7B |
| Intangible Assets Excluding Goodwill | $9.7B |
| Goodwill | $6.5B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $753M |
| Other Non Current Assets | - |
| Total Liabilities | $11B |
| Total Current Liabilities | $5.5B |
| Current Accounts Payable | $424M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.7B |
| Total Non Current Liabilities | $5.8B |
| Capital Lease Obligations | $335M |
| Long Term Debt | $4.5B |
| Current Long Term Debt | $1.7B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $6.6B |
| Other Current Liabilities | $2.8B |
| Other Non Current Liabilities | $732M |
| Total Shareholder Equity | $17B |
| Treasury Stock | - |
| Retained Earnings | $19B |
| Common Stock | $100K |
| Common Stock Shares Outstanding | $146M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $2.9B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $673M |
| Capital Expenditures | $360M |
| Change In Receivables | - |
| Change In Inventory | -$274M |
| Profit Loss | - |
| Cashflow From Investment | -$799M |
| Cashflow From Financing | -$684M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $1.6B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $7.4B |
| Total Revenue | $9.7B |
| Cost Of Revenue | $2.3B |
| Costof Goods And Services Sold | $2.3B |
| Operating Income | $2.5B |
| Selling General And Administrative | $2.3B |
| Research And Development | $2.5B |
| Operating Expenses | $4.9B |
| Investment Income Net | - |
| Net Interest Income | -$183M |
| Interest Income | $68M |
| Interest Expense | $250M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $673M |
| Income Before Tax | $1.9B |
| Income Tax Expense | $274M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.6B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.3B |
| Ebitda | $3B |
| Net Income | $1.6B |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Biogen Inc. is a leading biotechnology firm based in Cambridge, Massachusetts, renowned for its pioneering work in the discovery and development of innovative therapies for neurological disorders. The company boasts a comprehensive pipeline that addresses critical conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, positioning itself as a key player in meeting substantial unmet medical needs. Committed to advancing therapeutic innovation, Biogen leverages strategic partnerships and a deep commitment to scientific research, reinforcing its status as a prominent leader within the biotechnology industry and its dedication to improving patient outcomes.